Optune Lua/Optune
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.optunelua.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Optune Lua/Optune
Novocure Inc. offers Optune Lua, an FDA-approved device for treating metastatic non-small cell lung cancer (mNSCLC) in adults who have progressed on or after platinum-based chemotherapy, and when used together with PD-1/PD-L1 inhibitors or docetaxel. Healthcare professionals and patients can access important safety information, patient manuals, and educational materials through Novocure's website to learn more about Optune Lua. Intended for US audiences, Optune Lua is a wearable, portable device that aims to provide innovative treatment options for eligible mNSCLC patients.Explore more
Popular SearchesOptune Lua/OptuneIntouch Group LLCMalignant Pleural MesotheliomaOptune LuaSIC Code 38,384NAICS Code 33,339Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Optune Lua/Optune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Optune Lua/Optune has new funding data
Earning: See what the market has to say on Optune Lua/Optune recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Optune Lua/Optune has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Optune Lua/Optune
Optune Lua/Optune, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Optune Lua/Optune had a recent Job posting/layoffs
Product Launch: Get notified when Optune Lua/Optune launches new products
Check out if Optune Lua/Optune is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Optune Lua/Optune
Compare insights from companies similar to Optune Lua/Optune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Optune Lua/Optune
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Optune Lua/Optune is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Optune Lua/Optune is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Optune Lua/Optune.
Optune Lua/Optune Tech Stack
A closer look at the technologies used by Optune Lua/Optune
See more technologies
Optune Lua/Optune News & Media
Malignant Pleural Mesothelioma Market Poised for Growth Across the 7MM During the Study Period (2020–2034) Amid Advances in Immunotherapy and Targeted Drugs | DelveInsight
The malignant pleural mesothelioma market is poised for steady growth during the forecast period (2025–2034). The launch of innovative therapies by companies such as AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS Oncology, and others will drive this expansion across the 7MM. The malignant pleural mesothelioma market is poised for steady growth during the forecast period (2025–2034). The launch of innovative therapies by companies such as AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Optune Lua/Optune
Sign Up For FreeTo access detailed company insights
Novocure Inc. offers Optune Lua, an FDA-approved device for treating metastatic non-small cell lung cancer (mNSCLC) in adults who have progressed on or after platinum-based chemotherapy, and when used together with PD-1/PD-L1 inhibitors or docetaxel. Healthcare professionals and patients can access important safety information, patient manuals, and... Read More
